Enrollment has begun for a new phase 1 study of chimeric antigen receptor (CAR) T-cell therapy at UCHealth University of Colorado Hospital for adults with B-cell acute lymphoblastic leukemia (B-ALL). The trial is the first launched through the newly formed Gates Institute, and it will be the fourth for which the Gates Biomanufacturing Facility produces the CAR T product for research at CU Anschutz Medical Campus.
CU Anschutz
Anschutz Health Sciences Building
1890 N Revere Ct
Mailstop L606
Aurora, CO 80045